{
    "nctId": "NCT02876107",
    "briefTitle": "Carboplatin and Paclitaxel with or Without Panitumumab in Treating Patients with Invasive Triple Negative Breast Cancer",
    "officialTitle": "A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Carcinoma, Breast Lump, Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Peau D'orange, Progesterone Receptor Negative, Triple-Negative Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 42,
    "primaryOutcomeMeasure": "Complete pathologic response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have histological confirmation of breast carcinoma\n* Patients must have invasive breast cancer (IBC), confirmed according to international consensus criteria:\n\n  * Onset: Rapid onset of breast erythema, edema, and/or peau d'orange, and/or warm breast, with or without an underlying breast mass\n  * Duration: History of such findings no more than 6 months\n  * Extent: Erythema occupying at least 1/3 of whole breast\n  * Pathology: Pathologic confirmation of invasive carcinoma\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Patients must have negative HER2 expression on immunohistochemistry (IHC) (defined as 0 or 1+) or fluorescence in situ hybridization (FISH) analysis; if HER2 is 2+, negative HER2 expression must be confirmed by FISH (HER2/cep17 ration \\< 2, and/or copy number less than 6); ER and PgR expression should be less than 10%\n* Patients have left ventricular ejection fraction (LVEF) \\>= 50% by multigated acquisition scan (MUGA) or echocardiogram before study randomization\n* Absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9/L\n* Platelet count \\>= 100 x 10\\^9/L\n* Hemoglobin \\>= 9.0 g/dL\n* Aspartate aminotransferase (AST) =\\< 3.0 x upper limit of normal (ULN)\n* Alanine aminotransferase (ALT) =\\< 3.0 x ULN\n* Alkaline phosphatase (ALP) =\\< 2.5 x ULN\n* Total bilirubin =\\< 1.5 x ULN\n* Creatinine (Cr) =\\< 1.5 mg/dL x ULN\n* Creatinine clearance (CrCl) \\>= 50 mL/min calculated by the Cockroft-Gault\n* Patients have the ability and willingness to sign written informed consent\n* Patients of childbearing potential (women who are postmenopausal for \\< 1 year, not surgically sterilized, or not abstinent), have a negative urine pregnancy test, and agree to the consistent and correct use of one of the following acceptable methods of birth control: male partner who is sterile before the female subject's entry into the study and is the sole sexual partner for that female subject; intrauterine device, oral contraception, or barrier methods, including diaphragm or condom with a spermicide\n\nExclusion Criteria:\n\n* Stage IV disease, if the metastatic sites are not amendable for local therapy (i.e. radiation and/or surgery), and are not candidates for breast surgery will not be eligible\n* History of radiotherapy for current breast cancer diagnosis\n* History of recent malignancies \\< 5 years (except for cured non-melanomatous skin cancer or cured cervical carcinoma in situ)\n* Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection\n* History of extensive interstitial lung disease, e.g., pneumonitis or pulmonary fibrosis or any evidence of extensive interstitial lung disease on baseline chest computed tomography (CT) scan\n* Other known other significant medical or psychiatric condition that would make assessment of toxicity or efficacy difficult\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Patients with a peripheral neuropathy \\> grade 1\n* Patients with a history of New York Heart Association class 3 or 4 heart failure, or history of myocardial infarction, unstable angina, or cerebrovascular accident (CVA) within 6 months of protocol registration\n* Patients have a history of prior therapy with carboplatin\n* Patients have received a cumulative dose of doxorubicin of greater than 360 mg/m\\^2 or epirubicin of greater than 640 mg/m\\^2\n* Patients have had prior radiotherapy for primary breast carcinoma or axillary lymph nodes\n* Patients have history of diagnosed interstitial lung disease",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}